Skip to main content

Table 7 WOMAC, activity and mood scores (higher scores indicate more impairment: scaled from 0 to 100 except for knee circumference).

From: S-Adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: A double-blind cross-over trial. [ISRCTN36233495]

  

Baseline

SAMe

Celecoxib

 

Variable

N+

Mean

(SD)

Mean

(SD)

Mean

(SD)

Stdif.

WOMAC Knee Assessment

Tenderness

50

29.9

(21.8)

14.7*

(17.4)

19.3*

(18.9)

0.21

Swelling

51

15.7

(15.6)

9.8*

(14.6)

8.2*

(12.2)

-0.11

Fluid

49

6.6

(14.1)

6.8

(14.8)

4.4

(10.1)

-0.14

Knee Circumference (cm)

Total

50

41.6

(4.8)

41.5

(4.7)

42.1

(5.0)

0.52**

Above patella

50

45.0

(6.0)

44.8

(5.7)

45.4

(5.7)

0.43**

Below patella

50

38.3

(3.7)

38.2

(3.8)

38.9*

(4.5)

0.40**

WOMAC Pain Frequency

Mild

49

73.3

(27.9)

57.1*

(28.4)

61.2*

(27.0)

0.12

Moderate

46

65.6

(19.4)

46.2*

(25.8)

38.6*

(24.6)

-0.24

Severe

46

45.7

(20.8)

26.6*

(22.6)

22.8*

(24.1)

-0.14

WOMAC Other

Pain – Walking

25

37.8

(31.3)

17.6*

(20.5)

19.2*

(22.7)

0.07

ADL

50

26.0

(13.0)

20.3*

(14.2)

17.8*

(15.2)

-0.19

Activity Score

53

55.6

(24.3)

37.0*

(27.4)

34.8*

(30.0)

-0.10

Mood Score

52

13.2

(14.8)

8.6*

(11.8)

9.9*

(12.2)

0.17

  1. Stdif: Standardized difference scores – positive numbers indicate a better response with SAMe. +Sample sizes are less than 57 due to missing data in either Phase 1 or Phase 2. *Difference between baseline and treatment is statistically significant (p < 0.05). ** Difference between SAMe and Celecoxib is statistically significant (p < 0.05).